High-risk retinoblastoma based on age at primary enucleation: a study of 616 eyes
Author:
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology
Link
http://www.nature.com/articles/s41433-019-0698-2.pdf
Reference25 articles.
1. Kaliki S, Patel A, Iram S, Ramappa G, Mohamed A, Palkonda VAR. Retinoblastoma in India: clinical presentation and outcome in 1457 Patients (2074 Eyes). Retina. 2019;39:379–91.
2. Fabian ID, Stacey AW, Chowdhury T, Duncan C, Karaa EK, Scheimberg I, et al. High-risk histopathology features in primary and secondary enucleated international intraocular retinoblastoma classification group D eyes. Ophthalmology. 2017;124:851–8.
3. Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422–7.
4. Kaliki S, Srinivasan V, Gupta A, Mishra DK, Naik MN. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015;122:1165–72.
5. Sreelakshmi KV, Chandra A, Krishnakumar S, Natarajan V, Khetan V. Anterior chamber invasion in retinoblastoma: not an indication for adjuvant chemotherapy. Invest Ophthalmol Vis Sci. 2017;58:4654–61.
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current screening and diagnostic approaches of retinoblastoma in limited setting;Acta Marisiensis - Seria Medica;2023-09-01
2. Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma;Investigative Opthalmology & Visual Science;2023-08-21
3. The survival analysis and feasibility study of Pars Plana Vitrectomy (PPV) in the treatment of retinoblastoma;Journal of Cancer Research and Clinical Oncology;2022-11-10
4. Anatomo-Clinical Aspects of Retinoblastoma: A Series of 144 Cases;Cureus;2022-05-27
5. Defining High-risk Retinoblastoma;JAMA Ophthalmology;2022-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3